Can anti-cyclic citrullinated peptide antibody-negative RA be subdivided into clinical subphenotypes?

Arthritis Research and Therapy

Volumn 13, Issue 5, 2011, Pages

  De Rooy, Diederik P C ^a   Willemze, Annemiek ^a   Mertens, Bart ^a   Huizinga, Tom W J ^a   Van der Helm van Mil, Annette H M ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIC CITRULLINATED PEPTIDE ANTIBODY; AUTOANTIBODY; CYCLIC CITRULLINATED PEPTIDE; CYCLOPEPTIDE;

ADULT; ANTIBODY DETECTION; ARTICLE; CLUSTER ANALYSIS; DISEASE COURSE; DISEASE PREDISPOSITION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW UP; FOOT RADIOGRAPHY; GENETIC RISK; HAND RADIOGRAPHY; HUMAN; MAJOR CLINICAL STUDY; MALE; PARTIAL LEAST SQUARES REGRESSION; PHENOTYPE; PRINCIPAL COMPONENT ANALYSIS; RHEUMATOID ARTHRITIS; RISK FACTOR; SCORING SYSTEM; AGED; BIOSYNTHESIS; BLOOD; COHORT ANALYSIS; COMPARATIVE STUDY; EVIDENCE BASED MEDICINE; HEALTH SURVEY; IMMUNOLOGY; IMMUNOPHENOTYPING; METHODOLOGY; MIDDLE AGED;

ADULT; AGED; ARTHRITIS, RHEUMATOID; AUTOANTIBODIES; COHORT STUDIES; EVIDENCE-BASED MEDICINE; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOPHENOTYPING; MALE; MIDDLE AGED; PEPTIDES, CYCLIC; POPULATION SURVEILLANCE; RISK FACTORS;

EID: 80054904658     PISSN: 14786354     EISSN: 14786362     Source Type: Journal    
DOI: 10.1186/ar3505     Document Type: Article

References (10)

1. van der Helm-van Mil AH, Huizinga TW. Advances in the genetics of rheumatoid arthritis point to subclassification into distinct disease subsets. Arthritis Res Ther 2008, 10:205. 10.1186/ar2384, 2453775, 18394179.
2. Pratt AG, Charles PJ, Chowdhury M, Wilson G, Venables PJ, Isaacs JD. Serotyping for an extended anti-citrullinated peptide autoantibody panel does not add value to CCP2 testing for diagnosing RA in an early undifferentiated arthritis cohort. Ann Rheum Dis 2011, 70:2056-2058. 10.1136/ard.2010.148197, 21622767.
3. Padyukov L, Seielstad M, Ong RT, Ding B, Ronnelid J, Seddighzadeh M, Alfredsson L, Klareskog L. A genome-wide association study suggests contrasting associations in ACPA-positive versus ACPA-negative rheumatoid arthritis. Ann Rheum Dis 2011, 70:259-265. 10.1136/ard.2009.126821, 3015094, 21156761.
4. van Oosterhout M, Bajema I, Levarht EW, Toes RE, Huizinga TW, van Laar JM. Differences in synovial tissue infiltrates between anti-cyclic citrullinated peptide-positive rheumatoid arthritis and anti-cyclic citrullinated peptide-negative rheumatoid arthritis. Arthritis Rheum 2008, 58:53-60. 10.1002/art.23148, 18163491.
5. Klareskog L, Catrina AI, Paget S. Rheumatoid arthritis. Lancet 2009, 373:659-672. 10.1016/S0140-6736(09)60008-8, 19157532.
6. de Rooy DP, van der Linden MP, Knevel R, Huizinga TW, van der Helm-van Mil AH. Predicting arthritis outcomes: what can be learned from the Leiden Early Arthritis Clinic?. Rheumatology (Oxford) 2011, 50:93-100.
7. Nell VP, Machold KP, Stamm TA, Eberl G, Heinzl H, Uffmann M, Smolen JS, Steiner G. Autoantibody profiling as early diagnostic and prognostic tool for rheumatoid arthritis. Ann Rheum Dis 2005, 64:1731-1736. 10.1136/ard.2005.035691, 1755298, 15878904.
8. Chun H, Ballard DH, Cho J, Zhao H. Identification of association between disease and multiple markers via sparse partial least-squares regression. Genet Epidemiol 2011, 35:479-486.
9. Eisen MB, Spellman PT, Brown PO, Botstein D. Cluster analysis and display of genome-wide expression patterns. Proc Natl Acad Sci USA 1998, 95:14863-14868. 10.1073/pnas.95.25.14863, 24541, 9843981.
10. van der Helm-van Mil AH, Verpoort KN, Breedveld FC, Toes RE, Huizinga TW. Antibodies to citrullinated proteins and differences in clinical progression of rheumatoid arthritis. Arthritis Res Ther 2005, 7:R949-R958. 10.1186/ar1767, 1257421, 16207336.